WO2000057187A3 - Diagnosis and treatment of multiple sclerosis - Google Patents
Diagnosis and treatment of multiple sclerosis Download PDFInfo
- Publication number
- WO2000057187A3 WO2000057187A3 PCT/US2000/007226 US0007226W WO0057187A3 WO 2000057187 A3 WO2000057187 A3 WO 2000057187A3 US 0007226 W US0007226 W US 0007226W WO 0057187 A3 WO0057187 A3 WO 0057187A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multiple sclerosis
- diagnosis
- treatment
- patients
- chlamydia
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00916513A EP1166117A2 (en) | 1999-03-19 | 2000-03-17 | Diagnosis and treatment of multiple sclerosis |
AU37604/00A AU3760400A (en) | 1999-03-19 | 2000-03-17 | Methods and reagents for the diagnosis and treatment of multiple sclerosis |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12559899P | 1999-03-19 | 1999-03-19 | |
US60/125,598 | 1999-03-19 | ||
US17694000P | 2000-01-18 | 2000-01-18 | |
US17678400P | 2000-01-18 | 2000-01-18 | |
US17666200P | 2000-01-18 | 2000-01-18 | |
US60/176,662 | 2000-01-18 | ||
US60/176,784 | 2000-01-18 | ||
US60/176,940 | 2000-01-18 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000057187A2 WO2000057187A2 (en) | 2000-09-28 |
WO2000057187A3 true WO2000057187A3 (en) | 2001-04-19 |
WO2000057187A9 WO2000057187A9 (en) | 2001-10-25 |
Family
ID=27494587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/007226 WO2000057187A2 (en) | 1999-03-19 | 2000-03-17 | Diagnosis and treatment of multiple sclerosis |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1166117A2 (en) |
AU (1) | AU3760400A (en) |
WO (1) | WO2000057187A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0112969A (en) | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Method of using diketopiperazines and compositions containing them |
EP1408987B1 (en) * | 2001-07-13 | 2013-04-10 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
CA2500652A1 (en) * | 2002-10-02 | 2004-04-15 | Dmi Biosciences, Inc. | Diagnosis and monitoring of diseases |
PL2537524T3 (en) | 2003-05-15 | 2017-01-31 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
JP5856843B2 (en) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ,インコーポレイテッド | Pharmaceutical composition using diketopiperazine |
JP2013537195A (en) | 2010-09-07 | 2013-09-30 | ディエムアイ アクイジション コーポレイション | Disease treatment |
ES2795803T3 (en) | 2011-10-10 | 2020-11-24 | Ampio Pharmaceuticals Inc | Degenerative arthropathy treatment |
WO2013055749A1 (en) | 2011-10-10 | 2013-04-18 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
EA201490737A1 (en) | 2011-10-28 | 2014-09-30 | Ампио Фармасьютикалз, Инк. | TREATMENT OF RHINITIS |
CA2906864A1 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
US9956217B2 (en) | 2014-08-18 | 2018-05-01 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
WO2016209969A1 (en) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
CN109453165B (en) * | 2018-10-16 | 2021-02-05 | 丹诺医药(苏州)有限公司 | Solid dispersion of rifamycin-nitroimidazole coupled molecule and application thereof |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2134292A1 (en) * | 1971-04-30 | 1972-12-08 | Inst Nat Sante Rech Med | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine |
US3996355A (en) * | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
EP0439330A2 (en) * | 1990-01-25 | 1991-07-31 | Zeneca Limited | Amplification methods |
US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
US5650405A (en) * | 1993-05-05 | 1997-07-22 | Palo Alto Medical Foundation | Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S. |
CN1156589A (en) * | 1996-02-09 | 1997-08-13 | 王成武 | Application of rifampicin in Linxiao'an medicine for treating gonorrhea |
WO1998006435A2 (en) * | 1996-08-14 | 1998-02-19 | Vanderbilt University | COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY $i(CHLAMYDIA) |
WO1998010789A1 (en) * | 1996-09-12 | 1998-03-19 | Connaught Laboratories Limited | Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof |
US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
CN1190581A (en) * | 1998-02-25 | 1998-08-19 | 高绪侠 | Complex rifampin injection |
WO1998050074A2 (en) * | 1997-05-06 | 1998-11-12 | Vanderbilt University | Compositions of antichlamydial agents for the diagnosis and management of infection caused by chlamydia |
WO2000001378A1 (en) * | 1998-06-30 | 2000-01-13 | Karl William Baumgart | Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection |
-
2000
- 2000-03-17 EP EP00916513A patent/EP1166117A2/en not_active Withdrawn
- 2000-03-17 WO PCT/US2000/007226 patent/WO2000057187A2/en not_active Application Discontinuation
- 2000-03-17 AU AU37604/00A patent/AU3760400A/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2134292A1 (en) * | 1971-04-30 | 1972-12-08 | Inst Nat Sante Rech Med | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine |
US3996355A (en) * | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
EP0439330A2 (en) * | 1990-01-25 | 1991-07-31 | Zeneca Limited | Amplification methods |
US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
US5650405A (en) * | 1993-05-05 | 1997-07-22 | Palo Alto Medical Foundation | Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S. |
CN1156589A (en) * | 1996-02-09 | 1997-08-13 | 王成武 | Application of rifampicin in Linxiao'an medicine for treating gonorrhea |
WO1998006435A2 (en) * | 1996-08-14 | 1998-02-19 | Vanderbilt University | COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY $i(CHLAMYDIA) |
US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
WO1998010789A1 (en) * | 1996-09-12 | 1998-03-19 | Connaught Laboratories Limited | Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof |
WO1998050074A2 (en) * | 1997-05-06 | 1998-11-12 | Vanderbilt University | Compositions of antichlamydial agents for the diagnosis and management of infection caused by chlamydia |
CN1190581A (en) * | 1998-02-25 | 1998-08-19 | 高绪侠 | Complex rifampin injection |
WO2000001378A1 (en) * | 1998-06-30 | 2000-01-13 | Karl William Baumgart | Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection |
Non-Patent Citations (10)
Title |
---|
BERTRAND A ET AL: "[ Ofloxacin (RU 43280). Clinical study]. L'ofloxacine (RU 43280). Etude clinique.", PATHOLOGIE BIOLOGIE, (1987 MAY) 35 (5) 629-33., XP000949930 * |
DRANCOURT, MICHEL ET AL: "Oral rifampin plus ofloxacin for treatment of Staphylococcus infected orthopedic implants.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1993) VOL. 37, NO. 6, PP. 1214-1218., XP000949491 * |
FREIDANK, HEIKE M. ET AL: "In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations", ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1808-1810, XP000949492 * |
LAYH-SCHMITT GERLINDE; BENDL CLAUDIA; HILDT ULRIKE; DONG-SI TUAN ET AL.: "Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis", ANNALS OF NEUROLOGY, vol. 47, May 2000 (2000-05-01), pages 652 - 655, XP000949277 * |
SRIRAM S; MITCHELL W; STRATTON C: "Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS", NEUROLOGY, vol. 50, February 1998 (1998-02-01), pages 571 - 572, XP000949278 * |
SRIRAM SUBRAMANIAM; STRATTON CHARLES W; YAO SONG-YI; THARP ANTHONY; DING LINGMEI; BANNAN JASON D; MITCHELL WILLIAM M: "Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis", ANNALS OF NEUROLOGY, vol. 46, July 1999 (1999-07-01), pages 6 - 14, XP000949276 * |
SRIRAM SUBRAMANIAM; YAO SONG-YI; STRATTON CHARLES; MITCHELL WILLIAM: "C. pneumoniae infection of the CNS in patients with relapsing remitting MS", NEUROLOGY (51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; TORONTO, ONTARIO, CANADA; APRIL 17-24, 1999), vol. 52, 12 April 1998 (1998-04-12), pages A558 - A559, XP000949282 * |
YAO S -Y; SRIRAM S; STRATTON C; MITCHELL W: "Association between C. pneumoniae and MS", JOURNAL OF NEUROIMMUNOLOGY (FIFTH INTERNATIONAL CONGRESS OF THE INTERNATIONAL SOCIETY OF NEUROIMMUNOLOGY; MONTREAL, CANADA; AUGUST 23-27, 1998), vol. 90, 1 September 1998 (1998-09-01), pages 70, XP000949273 * |
YAO SONGYI; SRIRAM S; MITCHELL W; STRATTON C; THARP A: "CNS infection with C. pneumoniae in MS", NEUROLOGY (50TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; MINNEAPOLIS, MINNESOTA, USA; APRIL 25-MAY 2, 1998), vol. 50, April 1998 (1998-04-01), pages A423 - A424, XP000949281 * |
YAO SONG-YI; SRIRAM SUBRAMANIAM: "Reactivity of oligoclonal bands seen in CSF to C. pneumoniae antigens in patients with multiple sclerosis", NEUROLOGY (51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; TORONTO, ONTARIO, CANADA; APRIL 17-24, 1999), vol. 52, 12 April 1999 (1999-04-12), pages A559, XP000949279 * |
Also Published As
Publication number | Publication date |
---|---|
EP1166117A2 (en) | 2002-01-02 |
AU3760400A (en) | 2000-10-09 |
WO2000057187A2 (en) | 2000-09-28 |
WO2000057187A9 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000057187A3 (en) | Diagnosis and treatment of multiple sclerosis | |
MXPA01008882A (en) | Method and system for the discovery of cookies and other client information. | |
AU2001268331A1 (en) | Methods for diagnosing and treating thalamocortical dysrhythmia | |
MXPA01007973A (en) | Monitored vehicle tire and monitor retainer assembly. | |
AU5718596A (en) | Sonicated dextrose-albumin ultrasound contrast agent, contai ning perfluorobutane | |
AU2002243370A1 (en) | Body supported activity and condition monitor | |
CA2429020A1 (en) | Use of cci-779 as an antineoplastic agent | |
AU2001262943A1 (en) | Methods for drug discovery, disease treatment, and diagnosis using metabolomics | |
EP2329829A3 (en) | Use of uridine in combination with choline for the treatment of memory disorders | |
IL138814A0 (en) | Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases | |
WO1995024650A3 (en) | Methods of diagnosing and treating preeclampsia | |
EP1144639A3 (en) | Compounds and methods for the diagnosis and treatment of ehrlichia infection | |
AU6425800A (en) | Agents for the diagnosis, prognosis and treatment of malignant diseases | |
WO2003084384A3 (en) | Diagnosis of flavivirus infection | |
EP0681787A3 (en) | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis. | |
WO2001007644A3 (en) | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease | |
HK1042523A1 (en) | Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders | |
ZA992192B (en) | Humectant and lubricant solution for ophthalmic use. | |
CA2381354A1 (en) | Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines | |
WO2000071081A3 (en) | Methods of diagnosis and treatment of meniere disease | |
AU2002365941A1 (en) | Methods of diagnosis, monitoring and treatment of fertility | |
AU1569700A (en) | Novel therapeutic application of low molecular weight heparin | |
CA2402668A1 (en) | Use of cdp-choline for the prophylactic treatment of cerebral ischemia | |
WO2002072883A3 (en) | Nucleotide carrier for diagnosing and treating oral diseases | |
AU6107999A (en) | 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000916513 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/19-19/19, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 2000916513 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000916513 Country of ref document: EP |